---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044801"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:54:16.571435+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones

## Summary
- Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
- Upfront cash payment $10M; $9M paid at closing, $1M held in escrow for 15 months.
- Potential milestone payments up to $50M contingent on development, regulatory, and commercial milestones.
- Lilly assumes certain liabilities and will be responsible for all future clinical development of FXR314.
- Director Vaidehi Joshi resigned March 21, 2025, effective immediately, with no disagreement with the Company.

## SEC filing metadata
- accession: 0000950170-25-044801
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000095017025044801/0000950170-25-044801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000095017025044801/onvo-20250321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044801
- JSON: https://secwatch.observer/filing/0000950170-25-044801.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044801.txt

## Key facts
- Executive change
  Vaidehi Joshi resigned as Director at VivoSim Labs, INC..
  - Action: resigned
  - Role: Director
  source text: On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1497253/000095017025044801/0000950170-25-044801-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.